Opinion

Video

Evaluating Amivantamab and Lazertinib: Key Findings from the CHRYSALIS-2 Study at ASCO 2024

Author(s):

Jason Porter, MD

A key opinion leader examines the combination therapy of amivantamab and lazertinib in the CHRYSALIS-2 study for treatment-naïve patients or those with 2 or more prior lines of therapy, and its potential implications for non-small cell lung cancer treatment.

Video content above is prompted by the following questions:

  • Discuss the data that was presented at the ASCO 2024 on combination use amivantamab and lazertinib in the CHRYSALIS-2 study for patients who were treatment-naïve or had ≤ 2 prior lines.
  • Based on this study, how do you think amivantamab plus lazertinib compares with other current therapies used for EGFR mutations in NSCLC?
  • How might the safety data from this study impact treatment decisions and management strategies in clinical practice?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Related Content
AJMC Q&A with Robert Kratzke | Background image credit: ipopba - stock.adobe.com
July 22nd 2025

Making Reflexive Testing the Standard of Care in Lung Cancer: Robert Kratzke, MD

Hayden E. Klein Robert Kratzke, MD
There is a great need to streamline the process from the tissue sample to the diagnostic lab, whether it's genomic or immunohistochemistry, Robert Kratzke, MD, says.
AJMC Q&A with Robert Kratzke | Background image credit: ipopba - stock.adobe.com
July 15th 2025

Ensuring Coverage of Faster Biomarker Testing in Lung Cancer: Robert Kratzke, MD

Hayden E. Klein Robert Kratzke, MD
Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s both cost-effective and life-saving.
Lung cancer | Image credit: appledesign - stock.adobe.com
July 14th 2025

HALP Score Acts as Prognostic Biomarker for Survival Outcomes in NSCLC

Julia Bonavitacola
The hemoglobin, albumin, lymphocyte, and platelet (HALP) score can help to guide treatment decisions in patients living with non–small cell lung cancer (NSCLC).
IV chemotherapy-Aidman-stock.adobe.com
July 11th 2025

Patients With Advanced NSCLC Face Critical Treatment Gaps

Giuliana Grossi
New research reveals critical gaps in treatment for advanced non–small cell lung cancer (NSCLC), emphasizing the need for innovative therapies to improve patient outcomes.
FDA Approved
July 7th 2025

FDA Approves Sunvozertinib in Non–Small Cell Lung Cancer

Julia Bonavitacola
The treatment marks the only targeted oral treatment in patients with non–small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.
Alexander I. Spira, MD, PhD | Image: Virginia Cancer Specialists
July 3rd 2025

COCOON Shows How Prophylactic AE Management Boosts QOL When Treating NSCLC With Amivantamab Plus Lazertinib

Alexander I. Spira, MD, PhD Interview by Mary Caffrey
The COCOON trial reveals that prophylactic treatment reduces dermatological adverse events in NSCLC patients, enhancing their quality of life during amivantamab therapy.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo